Previous close | 6.97 |
Open | 7.65 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 48.00 |
Expiry date | 2024-06-21 |
Day's range | 6.96 - 7.65 |
Contract range | N/A |
Volume | |
Open interest | 1.43k |
PRINCETON, N.J., June 03, 2024--Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations...
PRINCETON, N.J., June 01, 2024--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced....
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.